2022 World Conference on Lung Cancer (ePosters)-EP08.01-090. Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront

EP08.01-090. Association of Gender and Outcomes in Patients With Advanced NSCLC Treated With Immunotherapy Alone or in Combination With Chemotherapy Upfront

Back to course

Pdf Summary

This study aimed to assess the impact of gender on the outcomes of immunotherapy in advanced non-small cell lung cancer (NSCLC) patients. The study analyzed data from 285 patients with advanced NSCLC who were treated with immune checkpoint inhibitor (ICI) therapy alone or in combination with chemotherapy. Baseline characteristics of the patients were collected, and survival analyses were performed.<br /><br />The results showed that gender did not have a negative impact on the prognosis of patients treated with ICI alone or in combination with chemotherapy. There were no significant differences in overall survival (OS) or progression-free survival (PFS) between male and female patients in the overall population or in the ICI or ICIChT cohorts.<br /><br />Baseline characteristics, such as age, smoking status, performance status (PS), histology, and PD-L1 expression, were similar between male and female patients, except for age, smoking status, and non-squamous histology, which were more prevalent in male patients.<br /><br />In conclusion, this study found that female gender was not associated with worse outcomes in patients with advanced NSCLC treated with immunotherapy. The results suggest that gender alone does not impact the efficacy of immunotherapy in this patient population. Further studies are needed to prospectively evaluate the role of gender in immunotherapy outcomes.

Asset Subtitle

Teresa Gorria

Meta Tag

Speaker Teresa Gorria

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

gender impact

immunotherapy outcomes

non-small cell lung cancer

NSCLC patients

immune checkpoint inhibitor

chemotherapy combination

overall survival

progression-free survival

baseline characteristics

PD-L1 expression